• Diabetes, A CONDITION WHERE BLOOD GLUCOSE LEVELS CANNOT BE CONTROLLED, AFFECTS MORE THAN 10% OF THE ADULT POPULATION WORLDWIDE, AND MORE THAN 90% OF THOSE HAVE TYPE 2 DIABETES.
  • Although The Condition Can Subtimes Be Controlled Through Diet and Exercise, MANY PEOPLE NEED MEDICATIONS TO MANAGE THEI BLOOD GLUCOSE LEVELS ONCE THEIR CELLS STOP RESPONTING TO INSULIN, THE HORMONE THAT THAT CONTROLS BLOOD GLUCOSE.
  • UNCONTROLLED BLOOD GLUCOSE (SUGAR) CAN LEAD TO COMPLICATIONS THAT MAY INCLUDE CARDIOVASCULAR DIEPAR, HIGH BLOOD PRESSURE, NERVE AND EYE DAMAGE, AND KIDNEY DIEW.
  • Now, An Analysis of Studies Has Found That Newer Medications for Type 2 Diabetes May Help Reduce The Risk of Complications, particularly Cardiovascular Disease, in Subo People with Type 2 Diabetes.

ACCORDING TO THE INTERNATIONAL DIABETES FEDERATION, AROUND 537 MILLION ADULS ARE CURRENTLY LIVING WITH DIABETES, AND THE NUMBER IS PROJECTED TO RISE TO 643 MILLION BY 2030.

There are two main types of diabetes:

  1. Type 1 Occurs When The Body Stops Production Insulin, usually Becouse of An Immune System Reaction
  2. In Type 2, Cells Stop Responding to Insulin.

Type 2 Diabetes, Which is Responsible for 90% of Diabetes Cases, is offe linked to overweight, obesity or inactivity.

Sub People with Type 2 Diabetes Can Control The Blood Glucose Through A Combination of a Healthy Diet and Increased Physical Activity, But Many Rely on Medications to Reduce Blood Glucose.

These include:

  • Metformin – The Most Commonly prescribed Oral Treatment for Type 2 Diabetes Reddes The Amount of Glucose (Sugar) Made by The Liver, you say Glucose Absorption, and increase the Effect of Insulin On The Body
  • dipeptidyl peptidase-4 (dpp-4) inhibitors – BeSe Help a Pers’ Pancreas produces more insulin and less glucagon, to reduce their Blood Glucose Levels
  • Glucagon-Like Peptide-1 (LPG-1) Agonist Receiver – these stimulate insulin secretion, inhibit the production of glucagon and smawn stomach emptying; They have the added benefit of finding Weight Loss.
  • sodium-glucose transport 2 (SGLT2) inhibitors – These reduces The Amount of Glucose Reabsorbed by the Kidneys, Meaning that it is excreted in the urine.

A Meta-Analysis, Published in the Journal of the American Medical Associationyou have review more than 600 trials to assess the efficacy of sum of these medications.

The Researchers Found That SGLT2 Inhibitors and LPG-1 agonists were Associated With a Lower Risk of Major Cardiovascular Events, But the Drug Effects Varied with the Patients’ Age.

Cheng-Han Chen, MD, A BOARARD-CERTIFIED INTERENTAL CARDIOLOGIST AND MEDICAL DIRECTOR OF THE STRUCTURAL HEART PROGRE Medical News Today:

“While They Act Through Different Biochemical Pathways, Bush LP-1 agonists and sglt2 inhibitors have shown to decrease the Risk of Cardiovascular Disease. They Both Likely Accomplish This by Cardiovascular Improving Disease Risk Factors Such As Improving Blood Sugar Control, Improving Blood Pressure, Promoting Weight Less, Reducting Inflammation, and Improving Blood Vessel Function.

All Treatments Linked to Small Decias In Blood Glucose

The Reviewed 601 Published Trials of Older People to Investigate Where The Efficacy of Three Medications-DPP-4 Inhibitors, SGLT2 Inhibitors, and GLP-1 agonists-Was AFFEED BY THE AGE OR SEX OF PEOPLE WITH TYPE 2 DIABETES.

They look at what effect the medications had on Hemoglobin A1c (HBA1C) – Using A Blood Test that Measures The Previous 3 Mounts’ Blood Glucose Levels – and on The Occurrence of Major Adverse Cardiovascular Ents, Such as Heart Attack, Stroke, Or Death From Cardiovascular Disease.

People in the 592 HBA1C Trials had Mean Age of 58.9 Years (42.3% female), and for the 23 trials that reported Major Adverse Cardiovascular Events, The Mean Age Was 64 Years (35.3% female).

All Treatments reduced HBA1C by Between 0.5% and 1.5%. SGLT2 Inhibitors and LPG-1 Agonists Also Reduced The Risk of Major Adverse Cardiovascular Events.

WHY AGE COUPFFT DIABETES DRUG EFFICACY

“It is well establishing that all Three Medications are Effective at Lowering Blood Glucose, But Only Sgg2 Inhibitor and LP Glasgow in Scotland, United Kingdom, and Corresponding Author on The Review Paper, Told MNT.

“Our Findings Confirm This (Already Establish) Knowledge, But Also Show That The Cardiovascular Benefits of Sgg2 Inhibitors are Even Greater in Older Comprared with Younger People, Lift the Glucose Lowering Effects Being Less in Older People,” He noted.

SGLT2 Inhibitors were More Effective at Lowering HBA1C in Younger People, with efficacy decorate as age increase. Conversley, LPG-1 Agonists Lowered HBA1C More Effectively in Older People.

Chen Gave A Possible Explanation For This Finding, Telling MNT That: “The Decree in Blood Sugar Control Efficacy With Sglt2 Inhibitors in Older Patients May Be Related To Age-Related Decree in Kidney Function. Previous Studies Have Found That SGLT2 Inhibitors appeal to Lower HBA1C Less in Patients With Worse Kidney Function. ”

“GLP-1 agonists appeal to be less affected by this interaction,” I have added.

In The Trials of Major Adverse Cardiovascular Events, The Refound that the relative reduction was Greater in Older People On Sglt2 Inhibitors, and Less in Older People On LPG-1 agonists. However, LPG-1 Agonists Had More Effect in Younger, Female Participants.

WHICH DIABETES TREATMENT WORORTS BEST FOR WHO?

“Both SGLT2 Inhibitors and LPG-1 agonists are Excellent Drug Categories that have improced the Heart Health of Patients by Improving Many Cardiovascular Risk Factors,” Said Chen.

This review suggests that there may be benefits in taking a patient’s age action when deciding which medications to prescribe for type 2 diabetes.

Although All of the Patients in This Review Were Middle-Aced and Older, The Results Suggest that SGLT2 Inhibitors Conferred Cardiovascular Greater Benefits in the Older Patients, While Glp-1 Agonists Conferred Greater Benefits in Those Who Were Younger, particularly Women.

Hanlon Explained How their Findings Might influence prescribing:

“Clinicians Already Balance A Range of Factors When Decing on the Best Treatment for an individual. This Includes The Person’s Treatment Goals, Factors Such As Weight, Risks of Given Medication, Other Therapies People Are Taking, and Age. OUR Findings Show That SGLT2 Inhibitors Appear More Effective in Reducting Cardiovascular Events in Older People, and This May Be One Piece of Information that CliniciSn CAN Take pole accouunt when deciding with individual patients what is best for them. ”

“Our Findings Also Suggest that Clinicicians Should Not Be Put Off by Smaller Changes in Blood Sugar in Older People, As The Cardiovascular Benefits Were Gretener Lower Smaller Improvement in Blood Sugar,” I have add.